Avapritinib and Decitabine for SM-AHN
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a combination of two drugs, avapritinib and decitabine, for people with systemic mastocytosis plus another blood cancer (SM-AHN). The goal is to see if the combination works better than either drug alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a diagnosis of SM-AHN (systemic mastocytosis with another blood cancer).
- You should be able to care for yourself (ECOG score 0-3) and be willing to follow study procedures.
- You cannot have tried decitabine or avapritinib before and had your disease worsen.
- You cannot have acute myeloid leukemia (AML) with 20% or more blasts in your blood or bone marrow.
- You must have adequate organ function and agree to use contraception if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how avapritinib works in people with indolent systemic mastocytosis whose symptoms are not well controlled by other treatments. You will take the drug as part of your usual care, and researchers will collect information to see how well it helps.
This study tests whether adding a new drug called iadademstat to the standard treatment ASTX727 helps people with advanced myeloproliferative neoplasms (blood cancers that cause the bone marrow to make too many cells). The goal is to see if the combination is safe and works better than the standard treatment alone.
This Phase 2 study tests bezuclastinib, a targeted medicine, in people with advanced systemic mastocytosis (including certain advanced forms with blood cancers). It aims to shrink measurable disease and improve symptoms, while helping people who may also need treatment for an associated blood cancer.
This study is observing adults with indolent systemic mastocytosis (ISM) who are already receiving or planning to start symptom treatments or the drug avapritinib. It aims to learn more about how these treatments work in real life.
This trial tests a new drug called axatilimab, given alone or with another drug, for people with certain blood cancers that are advanced or hard to treat. The goal is to see if this combination can help control the disease.
This early-phase trial tests whether a combination of targeted medicines can improve outcomes in people with higher-risk MDS or certain types of AML or CMML. It’s designed to find the safest dose and learn if the treatment can help the cancer respond.
Hear when a new Systemic Mastocytosis With an Associated Hematologic Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.